March 13, 2004 - Proneuron obtains $ 3.2m commitment; Proneuron Technologies ; Shepherd Center; Marcus Foundation
Privately-held Israeli biopharmaceutical firm Proneuron Technologies and the Shepherd Center, one of the world's leading centers for the treatment of traumatic spinal cord and brain injuries, have announced the receipt of a $ 3.2 million commitment by the Marcus Foundation.
The commitment will aid the financing of establishing of a cell-processing center in Atlanta, USA, and to support the Shepherd Center's participation in Proneuron's international, multi-center, randomized-controlled Phase II study of ProCord, an experimental procedure for acute spinal cord injury.
"We have been following the development of this experimental procedure, ProCord, for more than a year and feel confident that the collaboration between Shepherd and Proneuron will significantly contribute to the further advancement of this research," said Bernie Marcus, chairman of the Marcus Foundation.
The information and materials on this Web site are provided for general informational purposes only and are not intended to be legal advice. We attempt to provide quality information, but the law changes frequently and varies from jurisdiction to jurisdiction. The information and materials provided are general in nature, and may not apply to a specific factual or legal circumstance. An attorney and client relationship should not be implied. Nothing on this Web site is intended to substitute for the advice of an attorney, therefore if you require legal advice please consult with a competent attorney licensed to practice in your jurisdiction. All attorneys, unless otherwise noted in website, are not certified by Texas Board of Legal Specialization. See Terms of Use.